Table 3 Adverse events at first and last data points during degeralix therapy
Adverse event n,% | First data pointa | Last data pointb |
|---|---|---|
Totalc | 276 (27.3) | 380 (37.6) |
Hot flushes | 80 (7.9) | 130 (12.9) |
Erythema at the injection site | 61 (6.0) | 86 (8.5) |
Fatigue | 41 (4.1) | 53 (5.2) |
Pain | 29 (2.9) | 42 (4.2) |
Weight gain | 20 (2.0) | 20 (2.0) |
Back pain | 10 (1.0) | 18 (1.8) |
Hypertension | 12 (1.2) | 6 (0.59) |
Cardiac arrhythmia | 3 (0.3) | 3 (0.3) |
Thromboembolism | 0 | 0 |
Heart attack | 2 (0.2) | 1 (0.1) |
Arteriosclerosis | 0 | 1 (0.1) |
Osteoporosis | 0 | 1 (0.1) |
Others | 18 (1.8) | 19 (1.9) |